The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

The landscape of drug discovery has been dramatically shifting, thanks in large part to the influence of artificial intelligence (AI).

Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing ...

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to ...

Charles Schwab Investment Management Inc. increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) ...

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.

When it comes to innovation, location matters. Because of Trump, China's dominance of the world economy could be nigh.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Ginkgo Bioworks (DNA) 7.32% +1.48, Kingsoft ...

Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of several that are developing AI models to make the process of diagnosis ...